Selim Aractingi

Selim Aractingi

Auto-generated profile, based on publicly available information

Selim Aractingi

Department of Dermatology, CERTIM Group, Cochin Port-Royal Hospital, AP-HP, University Paris Descartes, 123 Bd Port-Royal, 75 679, Paris Cedex 14, France

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
AVAxel Patrice Villani
Axel Patrice Villani
MRMarie Rouzaud
Marie Rouzaud
MSMorgane Sevrain
Morgane Sevrain
TBThomas Barnetche
Thomas Barnetche
CPCarle Paul
Carle Paul
DJDenis Jullien
Denis Jullien

18 April 2012 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
EAE. Archier
E. Archier
SDS. Devaux
S. Devaux
ECE. Castela
E. Castela
AGA. Gallini
A. Gallini
FAF. Aubin
F. Aubin
MRM.‐A. Richard
M.‐A. Richard

11 July 2013 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
CHC. Horreau
C. Horreau
CPC. Pouplard
C. Pouplard
EBE. Brenaut
E. Brenaut
TBT. Barnetche
T. Barnetche
LML. Misery
L. Misery
MRM.‐A. Richard
M.‐A. Richard
Previous epidemiological studies have demonstrated a high prevalence of cardiovascular (CV) risk factors in psoriasis patients, including metabolic syndrome, cigarette smoking, obesity, hypertension, diabetes mellitus, insulin resistance and dyslipidaemia. An increase in CV morbidity and mortality attributable to psoriasis is still under question.Primary objective: to assess CV morbidity and mortality in psoriasis and psoriatic arthritis (PsA) including stroke, coronary artery disease, myocardial infarction (MI) and peripheral artery disease. Secondary objectives: to assess if psoriasis per se is an independent CV risk factor and if psoriasis severity is a predictor of CV risk. We also evaluated the effect of conventional systemic treatments for psoriasis on CV mortality.A systematic literature search was carried out from 1980 to December 2011, in the Embase, Medline and Cochrane Library databases, in English and French using a combination of keywords including (Psoriasis) OR (Psoriatic arthritis) AND (Myocardial infarction) OR (Coronaropathy) OR (Stroke) OR (Cardiovascular) AND (Methotrexate) AND (Ciclosporin) AND (Retinoids).Of the 929 identified references, 33 observational studies evaluating the rates of cardiovascular events (CVE) in patients with psoriasis and PsA compared with controls were selected. Meta‐analysis of both cohort and cross‐sectional studies showed an increased risk of MI with Odds Ratio (OR) of 1.25 (95% CI 1.03–1.52) and 1.57 (95% CI 1.08–2.27) in psoriasis and PsA, respectively, compared with the general population. The risk of MI was more pronounced for patients having severe psoriasis and for patients with psoriasis of early onset. It remained significantly elevated after controlling for major CV risk factors. The meta‐analysis identified a small, but significant association between psoriasis, PsA and coronary artery disease with an OR between 1.19 (95% CI 1.14–1.24) for cross‐sectional studies, 1.20 (95% CI 1.13–1.27) for cohort studies and 1.84 (95% CI 1.09–3.09) for case–control studies. The risk of coronary artery disease seemed to be more pronounced in patients with severe psoriasis and in patients with psoriasis of early onset. The meta‐analysis assessing the risk of stroke gave inconclusive results: analysis of cross‐sectional studies suggested that psoriasis patients had a slightly higher risk of stroke with an OR of 1.14 (95% CI 1.08–1.99), whereas the meta‐analysis of cohort studies failed to show an association. There was also an increased risk of peripheral artery disease in psoriasis. No significant increased risk of CV mortality could be shown for both psoriasis and PsA patients. The use of methotrexate was associated with a reduced incidence of cardiovascular disease in two studies. The use of etretinate was associated with a reduction of CV mortality in one study. Potential selection bias such as the ‘healthy user effect’ prevents from drawing definite conclusions.There may be a small, but significant increased risk of CVE, but not of CV mortality in psoriasis and PsA patients. The psoriasis attributable risk remains difficult to assess due to confounding factors. The moderate quality of CV risk factors reporting in studies should be acknowledged. In addition, heterogeneity in study design, outcome definition and assessment represent major limitations. Nevertheless, screening and management of CV risk factors are important in psoriasis.

4 March 2010 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
EPE Puzenat
E Puzenat
VBV Bronsard
V Bronsard
SPS Prey
S Prey
PGP‐A Gourraud
P‐A Gourraud
SAS Aractingi
S Aractingi
FAFrançois Aubin
François Aubin

11 July 2013 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
CPC. Pouplard
C. Pouplard
EBE. Brenaut
E. Brenaut
CHC. Horreau
C. Horreau
TBT. Barnetche
T. Barnetche
LML. Misery
L. Misery
CPC. Paul
C. Paul
The relationship between psoriasis and increased cancer risk is debated.The aim of this study was to evaluate if there is an increase in the background risk of cancer in psoriasis patients compared with the general population.A systematic literature search was performed on PubMed, Embase and Cochrane databases, using the keywords ‘Psoriasis [Majr] AND Neoplasms’, from 1980 to January 2012. Meta‐analysis was performed based on observational studies showing consistency in cancer risk assessment methods.Of the 1080 articles retrieved, 37 references were selected. There may be an increased risk of some solid cancers in psoriasis: respiratory tract cancer [standardized incidence ratio (SIR) = 1.52, 95% confidence interval (CI) 1.35–1.71], upper aerodigestive tract cancer (SIR = 3.05, 95% CI 1.74–5.32), urinary tract cancer (SIR = 1.31, 95% CI 1.11–1.55) and liver cancer (SIR = 1.90, 95% CI 1.48–2.44). The risk of non‐Hodgkin lymphoma appears slightly increased in psoriasis (SIR = 1.40, 95% CI 1.06–1.86). Psoriasis patients have an increased risk of squamous cell carcinoma (SIR = 5.3, 95% CI 2.63–10.71) and basal cell carcinoma (SIR = 2.00, 95% CI 1.83–2.20), whereas the risk of melanoma is not increased.There was a large heterogeneity in studies assessing cancer risk in psoriasis preventing from including all studies in meta‐analysis.This systematic literature review shows a small increased risk of some solid cancers in psoriasis, especially those linked to alcohol drinking and cigarette smoking. A higher risk of non‐melanoma skin cancers, especially squamous cell carcinoma, is shown, mainly due to previous exposure to 8‐methoxypsoralen‐ultraviolet‐A (PUVA), ciclosporin and possibly methotrexate.

1 December 1998 in The Lancet
Verified
Journal Article
Closed access
SASélim Aractingi
Sélim Aractingi
NBNadia Berkane
Nadia Berkane
PBPhilippe Bertheau
Philippe Bertheau
CGCaroline Le Goué
Caroline Le Goué
JDJean Dausset
Jean Dausset
ECEdgardo D Carosella
Edgardo D Carosella